This report describes efforts to develop and validate novel norepinephrine transporter reuptake inhibition assays using human neuroblastoma SK-N-BE(2)C cells in 24-well format. Before conducting the assays, the SK-N-BE(2)C cells were first evaluated for their ability to uptake [ 3 H]norepinephrine and were shown to have a saturable uptake with a K M value of 416 nM. Using this determined K M value, reuptake inhibition assays were then conducted with a variety of ligands including antidepressants, as well as piperazine and phenyltropane derivatives. The results obtained with the SK-N-BE(2)C cells indicate that this model system can detect a range of ligand potencies, which compare well with other established transporter assays. Our data suggest that SK-N-BE(2)C cells have potential utility to serve as another model system to detect norepinephrine reuptake inhibition activity.
Introduction
Plasma membrane biogenic amine transporters (BATs) regulate monoamine neurotransmitter concentrations in the Central Nervous System (CNS) by transporting previously released monoamine neurotransmitters e dopamine, norepinephrine, and serotonin (DA, NE, and 5-HT, respectively) e from the synaptic cleft to the neuronal cytoplasm [1] . BATs play a major role in a plethora of physiological conditions including addiction, depression, anxiety, schizophrenia, and Parkinson's disease, and thus are the targets of many therapeutics and synthetic ligands [2] . Both types of transporter ligands (reuptake inhibitors and substrate-type releasers) elevate extracellular neurotransmitter concentrations, but they act by different mechanisms [3] .
Reuptake inhibitors bind to transporters and block transporter-mediated reuptake of neurotransmitters, while substrate-type releasers bind to the substrate site on the transporter, are transported inside the neuron, and promote neurotransmitter efflux by transporter-mediated exchange [4, 5, 6] .
Currently, two in vitro assays are widely used to measure transporter ligand activity using either rat brain synaptosomes or transfected HEK293 cells. In the rat brain synaptosome assay, freshly prepared functioning synaptosomes are incubated with test ligands and [
3 H]tracers to measure activity at rodent transporters [7] . The cell-based assay is performed similarly, except that HEK293 cells with over-expressed human transporters are used instead of synaptosomes [8] . Recently, we questioned whether it would be possible to develop a new cell-based in vitro assay that measured endogenous human transporter activity in a human derived cellular background, similar to the endogenous rodent transporter activity measured in synaptosomes. In this regard, we developed and validated an assay that measures endogenous serotonin transporter (SERT) reuptake inhibition activity in human derived choriocarcinoma JAR cells [9] . In this study, we showed that JAR cells were capable of detecting reuptake inhibition activity of known ligands with potencies that compared well with the rat brain synaptosomes and hSERT-HEK293 cells. Because of the positive results we obtained with JAR cells, we set out to develop a similar assay to measure norepinephrine transporter (NET) reuptake inhibition activity using human neuroblastoma SK-N-BE(2)C cells.
SK-N-BE(2)C cells were chosen to test NET activity because they have essential noradrenergic phenotypes. These cells synthesize norepinephrine, uptake norepinephrine in a specific manner, contain neurofilament proteins, and express biosynthetic enzymes such as dopamine b-hydroxylase [10, 11] . Because of these noradrenergic phenotypes, multiple studies have been conducted that characterize hNET function and regulation using these cells. For example, SK-N-BE(2)C cells have been used to examine the relationship between stress and hNET upregulation [12] , the role of transcription factors in the noradrenergic system (protein levels, NE uptake), [13] and the regulation of hNET gene expression [14] 
Protein determination
Protein concentration was determined using the Bradford assay (Pierce Coomassie Protein Assay Kit (ThermoFisher Scientific, 23200). Bovine Serum Albumin (BSA) was used as the standard and lysed cells were prepared at three different dilutions (1:2, 1:5, 1:8) in KRH wash buffer. The assay was run in triplicate by following the manufacturer's instructions. Absorbance was measured on a CLARIOstar (BMG Biotech, Cary NC) multi-mode plate reader (595 nm). The blank measurement (KRH wash buffer) was subtracted from all measurements and a standard curve was prepared by plotting the BSA standard absorbance against the concentration. The curve was fit to a second order polynomial quadratic curve and sample concentrations were interpolated. Experiments were repeated three times to obtain average protein concentrations for SK-N-BE(2)C cells (200,000 cells).
Uptake kinetics
On day 1, SK-N-BE(2)C cells were plated at 200,000 cells/well in 24-well polystyrene clear microplates pre-coated with rat tail type I collagen (86.9 mg/mL) and incubated overnight at 37 C, 5% CO 2 . On day 2, culture medium was removed, the cells were gently washed with 200 mL KRH assay buffer, and wells were filled with 150 mL KRH assay buffer. Assay plates were kept at RT for 15 minutes. Serial dilutions of the diluted [ 3 H]NE tracer were prepared at 8x the final desired concentration in KRH assay buffer and 25 mL was added to each well. 25 mL of 0.4% DMSO/ KRH (TB) or 25 mL of 5 mM final desipramine (NSB) were added and the cells were incubated for 1 hr, 30 min, 15 min, and 0 min at RT. At the end of each incubation, the assay buffer was removed and the cells were washed 2 times with 300 mL cold KRH wash buffer. Cells were lysed in 300 mL 1% Triton x-100 in KRH wash buffer with shaking for 60 min. Contents of each well were transferred to 7 mL scintillation vials and 5 mL Ultima Gold scintillation cocktail was added. Retained radioactivity was counted by a Packard Tri-Carb liquid scintillation counter. The counts (cpm) were converted to fmol radioactivity/mg protein and MB for each tracer concentration was calculated. The data were analyzed using a Michaelis-Menten enzyme kinetic nonlinear regression to determine V MAX and K M . The assay was terminated by removing the assay buffer and washing the cells 2x with 300 mL cold KRH wash buffer. Cells were lysed in 300 mL 1% Triton x-100
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in KRH wash buffer with shaking. Retained radioactivity was counted in 5 mL Ultima Gold scintillation cocktail using a Liquid Scintillation Counter and data were analyzed as described in the Methods 2.4 section.
Results and discussion

Uptake kinetics
Before conducting the reuptake inhibition assays, SK-N-BE (2) 
Reuptake inhibition activity of previously characterized ligands
The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and citalopram, the tricyclic antidepressant desipramine, the piperazine derivatives GBR12935 and GBR12909, the phenyltropane derivatives RTI-55 and RTI-229, and the nonselective monoamine transporter inhibitor indatraline were evaluated for reuptake inhibition activity in the SK-N-BE(2)C cells (Table 1 and with an IC 50 value of 66.7 nM, which is 4.9-fold less potent than rat brain synaptosomes (IC 50 ¼ 13.6 nM), and 9.7-fold more potent than hNET-HEK293 cells (IC 50 ¼ 645 nM).
It is important to note a potential limitation of the data comparison between the SK-N-BE(2)C cells and hNET-HEK293 cells in the present study. Half of the compounds [18] . c Data reported as mean AE S.E.M. in [8] . d Unpublished results generated by our group. Data are mean AE S.E.M. of at least three independent experiments conducted in duplicate as described in the Methods.
(fluoxetine, desipramine, GBR12935, RTI-55) were evaluated in hNET-HEK293 cells by Eshleman and colleagues [8] , while the rest (citalopram, GBR12909, RTI-229, indatraline) were not included in the Eshleman study and hence were evaluated by our laboratory (unpublished results). Generally, the results from the Eshleman study compare favorably with the rat brain synaptosomes while the results from our study do not, likely due to differences in the assay protocols wherein our lab measured reuptake inhibition in plated cells, while the Eshleman lab used cell suspensions. Because the literature is replete with examples of differences in compound potencies between different research groups using the same type of assay, it would be more ideal to compare the SK-N-BE(2)C potencies with hNET-HEK293 potencies generated from one lab. Given the lack of hNET-HEK293 data generated by one lab, it may be more appropriate to compare the SK-N-BE(2)C results only with rat brain synaptosomes. In this regard, the reuptake inhibition potencies generated in SK-N-BE(2)C cells are all less potent compared to rat brain synaptosomes (2-to 38-fold), speaking to the sensitivities of the two assays, but the rank order remains very well conserved between the methods. In SK-N-BE(2)C cells, the reuptake inhibition rank order potency (from most potent to least potent) is desipramine > RTI-55 > indatraline > RTI-229 > GBR12909 > GBR12935 > fluoxetine > citalopram. In rat brain synaptosomes, the rank order is exactly the same, except RTI-55 and desipramine are switched. The direct correlation between potency rank order further substantiates that SK-N-BE(2)C cells can potentially serve as another type of in vitro transporter assay.
Conclusions
This study demonstrates a novel method of assessing hNET reuptake inhibition activity using human neuroblastoma SK-N-BE ( 
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